bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

Core Insights - bioAffinity Technologies has initiated a longitudinal study involving 2,000 patients to evaluate its CyPath Lung noninvasive diagnostic for lung cancer [1] Company Summary - The study aims to assess the effectiveness of CyPath Lung, which is designed for the early detection of lung cancer [1] Industry Context - The launch of this study highlights the growing focus on noninvasive diagnostic methods in the healthcare industry, particularly for cancer detection [1]